Spots Global Cancer Trial Database for stage iv breast cancer ajcc v6 and v7

Every month we try and update this database with for stage iv breast cancer ajcc v6 and v7 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery	NCT02658812	Malignant Chest... Recurrent Breas... Recurrent Infla... Stage IV Breast... Stage IV Inflam...	Laboratory Biom... Talimogene Lahe...	18 Years -	M.D. Anderson Cancer Center
Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer	NCT02474173	Advanced Breast... Metastatic Brea... Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... Triple-Negative...	Laboratory Biom... Onalespib Paclitaxel Pharmacological...	18 Years -	National Cancer Institute (NCI)
Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer	NCT00601900	Invasive Breast... Recurrent Breas... Stage III Breas... Stage IV Breast...	Bevacizumab Laboratory Biom... Letrozole Questionnaire A... Tamoxifen Citra...	18 Years -	National Cancer Institute (NCI)
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer	NCT01142401	Metastatic Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast...	Bortezomib Fulvestrant Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies	NCT02706392	Hematopoietic a... Malignant Solid... Metastatic Lung... Metastatic Trip... Recurrent Acute... Recurrent Mantl... Refractory Chro... Stage III Lung ... Stage IIIA Lung... Stage IIIB Lung... Stage IV Breast... Stage IV Lung N... Unresectable Lu...	Laboratory Biom... ROR1 CAR-specif...	18 Years -	Fred Hutchinson Cancer Center
Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer	NCT03199885	Metastatic Brea... Metastatic HER2... Recurrent Breas... Recurrent HER2-... Stage III Breas... Stage IV Breast... Unresectable Br... Unresectable HE...	Atezolizumab Biopsy Bone Scan Computed Tomogr... Docetaxel Magnetic Resona... Paclitaxel Pertuzumab Placebo Adminis... Quality-of-Life... Trastuzumab	18 Years -	National Cancer Institute (NCI)
Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer	NCT01622868	HER2-Positive B... Invasive Breast... Metastatic Mali... Recurrent Breas... Stage IV Breast...	Laboratory Biom... Lapatinib Ditos... Stereotactic Ra... Whole-Brain Rad...	18 Years -	National Cancer Institute (NCI)
Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer	NCT03106415	Breast Adenocar... Metastatic Trip... Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast...	Binimetinib Laboratory Biom... Pembrolizumab	18 Years -	Mayo Clinic
Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer	NCT01463072	Locally Advance... Metastatic Brea... Recurrent Breas... Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast...	Laboratory Biom... Nab-paclitaxel Questionnaire A...	65 Years -	City of Hope Medical Center
Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer	NCT00684983	HER2 Positive B... Recurrent Breas... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast...	Capecitabine Cixutumumab Lapatinib Ditos... Quality-of-Life...	18 Years -	National Cancer Institute (NCI)
Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer	NCT00699491	Male Breast Car... Recurrent Breas... Stage IV Breast...	Cixutumumab Laboratory Biom... Pharmacological... Temsirolimus	18 Years -	National Cancer Institute (NCI)
Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast Cancer	NCT00376688	Recurrent Breas... Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast...	Laboratory Biom... Temsirolimus	18 Years -	National Cancer Institute (NCI)
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases	NCT02595905	Metastatic BRCA... Metastatic Brea... Metastatic Mali... Metastatic Trip... Recurrent Breas... Stage IV Breast...	Cisplatin Laboratory Biom... Placebo Adminis... Veliparib	18 Years -	National Cancer Institute (NCI)
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability	NCT03428802	BRCA1 Gene Muta... BRCA2 Gene Muta... Locally Advance... Metastatic Mali... POLD1 Gene Muta... POLE Gene Mutat... Recurrent Malig... Recurrent Ovari... Stage III Breas... Stage III Ovari... Stage IIIA Brea... Stage IIIA Ovar... Stage IIIB Brea... Stage IIIB Ovar... Stage IIIC Brea... Stage IIIC Ovar... Stage IV Breast... Stage IV Ovaria... Stage IVA Ovari... Stage IVB Ovari...	Laboratory Biom... Pembrolizumab	18 Years -	Rutgers, The State University of New Jersey
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors	NCT02498613	Advanced Malign... Metastatic Lung... Metastatic Lung... Metastatic Panc... Metastatic Trip... Pancreatic Duct... Stage III Breas... Stage III Lung ... Stage III Lung ... Stage III Pancr... Stage IIIA Brea... Stage IIIA Lung... Stage IIIA Lung... Stage IIIB Brea... Stage IIIB Lung... Stage IIIB Lung... Stage IIIC Brea... Stage IV Breast... Stage IV Lung N... Stage IV Lung S... Stage IV Pancre... Triple-Negative... Unresectable Lu... Unresectable Pa... Unresectable Pa... Unresectable Tr...	18F-Fluoromison... Cediranib Malea... Laboratory Biom... Olaparib Positron Emissi...	18 Years -	National Cancer Institute (NCI)
Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer	NCT02673398	HER2 Positive B... Stage IV Breast...	Comprehensive G... Laboratory Biom... Neratinib Pharmacological...	60 Years -	City of Hope Medical Center
Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer	NCT01349959	Male Breast Car... Recurrent Breas... Stage IIIC Brea... Stage IV Breast... Triple-Negative...	Azacitidine Entinostat Laboratory Biom... Pharmacological...	18 Years -	National Cancer Institute (NCI)
Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer	NCT02778685	Metastatic Brea... Stage IV Breast...	Fulvestrant Laboratory Biom... Letrozole Palbociclib Pembrolizumab	18 Years -	City of Hope Medical Center
Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer	NCT01351909	Locally Advance... Metastatic Brea... Recurrent Breas... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast...	Cyclophosphamid... Laboratory Biom... Veliparib	18 Years -	National Cancer Institute (NCI)
Ketogenic Diet and Chemotherapy in Affecting Recurrence in Patients With Stage IV Breast Cancer	NCT03535701	Stage IV Breast...	Dietary Interve... Laboratory Biom... Paclitaxel Quality-of-Life... Questionnaire A...	18 Years -	Ohio State University Comprehensive Cancer Center
Ketogenic Diet and Chemotherapy in Affecting Recurrence in Patients With Stage IV Breast Cancer	NCT03535701	Stage IV Breast...	Dietary Interve... Laboratory Biom... Paclitaxel Quality-of-Life... Questionnaire A...	18 Years -	Ohio State University Comprehensive Cancer Center
F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy	NCT02149173	Estrogen Recept... Recurrent Breas... Stage IV Breast...	Computed Tomogr... Computed Tomogr... F-18 16 Alpha-F... Fludeoxyglucose... Laboratory Biom... Positron Emissi... Positron Emissi...	18 Years -	University of Washington
Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer	NCT00684983	HER2 Positive B... Recurrent Breas... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast...	Capecitabine Cixutumumab Lapatinib Ditos... Quality-of-Life...	18 Years -	National Cancer Institute (NCI)
Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies	NCT02706392	Hematopoietic a... Malignant Solid... Metastatic Lung... Metastatic Trip... Recurrent Acute... Recurrent Mantl... Refractory Chro... Stage III Lung ... Stage IIIA Lung... Stage IIIB Lung... Stage IV Breast... Stage IV Lung N... Unresectable Lu...	Laboratory Biom... ROR1 CAR-specif...	18 Years -	Fred Hutchinson Cancer Center
Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy	NCT04692103	Estrogen Recept... Primary or Recu... Stage IV Breast...	F-18 16 Alpha-F... Positron Emissi... Computed Tomogr... Fludeoxyglucose... Positron Emissi... Computed Tomogr... Laboratory Biom...	18 Years -	University of Washington
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors	NCT02498613	Advanced Malign... Metastatic Lung... Metastatic Lung... Metastatic Panc... Metastatic Trip... Pancreatic Duct... Stage III Breas... Stage III Lung ... Stage III Lung ... Stage III Pancr... Stage IIIA Brea... Stage IIIA Lung... Stage IIIA Lung... Stage IIIB Brea... Stage IIIB Lung... Stage IIIB Lung... Stage IIIC Brea... Stage IV Breast... Stage IV Lung N... Stage IV Lung S... Stage IV Pancre... Triple-Negative... Unresectable Lu... Unresectable Pa... Unresectable Pa... Unresectable Tr...	18F-Fluoromison... Cediranib Malea... Laboratory Biom... Olaparib Positron Emissi...	18 Years -	National Cancer Institute (NCI)
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer	NCT01142401	Metastatic Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast...	Bortezomib Fulvestrant Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer	NCT01463072	Locally Advance... Metastatic Brea... Recurrent Breas... Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast...	Laboratory Biom... Nab-paclitaxel Questionnaire A...	65 Years -	City of Hope Medical Center
Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord	NCT02713269	Malignant Diges... Metastatic Head... Metastatic Kidn... Metastatic Mali... Metastatic Mali... Metastatic Mela... Prostate Carcin... Sarcoma Solid Neoplasm Spinal Cord Com... Stage IV Breast... Stage IV Lung N... Thyroid Gland C...	Computed Tomogr... Quality-of-Life... Questionnaire A... Stereotactic Ra... Thermal Ablatio...	18 Years -	M.D. Anderson Cancer Center
Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy	NCT04692103	Estrogen Recept... Primary or Recu... Stage IV Breast...	F-18 16 Alpha-F... Positron Emissi... Computed Tomogr... Fludeoxyglucose... Positron Emissi... Computed Tomogr... Laboratory Biom...	18 Years -	University of Washington
Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer	NCT03106415	Breast Adenocar... Metastatic Trip... Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast...	Binimetinib Laboratory Biom... Pembrolizumab	18 Years -	Mayo Clinic
Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer	NCT03101748	Breast Inflamma... Locally Advance... Metastatic Brea... Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast...	Cyclophosphamid... Doxorubicin Laboratory Biom... Neratinib Paclitaxel Pertuzumab Trastuzumab	18 Years -	M.D. Anderson Cancer Center
Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer	NCT03012230	Metastatic Mali... Stage IV Breast... Triple-Negative...	Laboratory Biom... Pembrolizumab Ruxolitinib Pho...	18 Years -	Mayo Clinic
MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer	NCT01344031	Estrogen Recept... Invasive Breast... Recurrent Breas... Stage IV Breast...	Akt Inhibitor M... Anastrozole Fulvestrant Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer	NCT01142401	Metastatic Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast...	Bortezomib Fulvestrant Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection	NCT05334069	Acute Lymphobla... Acute Myeloid L... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Chronic Lymphoc... Chronic Myeloid... Gastroesophagea... Head and Neck C... Hematopoietic a... Invasive Breast... Kidney Carcinom... Malignant Hepat... Malignant Solid... Melanoma Muscle-Invasive... RISS Stage I Pl... RISS Stage II P... RISS Stage III ... Sarcoma Stage I Bladder... Stage I Breast ... Stage I Colorec... Stage I Esophag... Stage I Gastric... Stage I Lung Ca... Stage I Ovarian... Stage I Pancrea... Stage I Prostat... Stage I Uterine... Stage II Bladde... Stage II Breast... Stage II Colore... Stage II Esopha... Stage II Gastri... Stage II Lung C... Stage II Ovaria... Stage II Pancre... Stage II Prosta... Stage II Uterin... Stage III Bladd... Stage III Breas... Stage III Color... Stage III Esoph... Stage III Gastr... Stage III Lung ... Stage III Ovari... Stage III Pancr... Stage III Prost... Stage III Uteri... Stage IV Bladde... Stage IV Breast... Stage IV Colore... Stage IV Esopha... Stage IV Gastri... Stage IV Lung C... Stage IV Ovaria... Stage IV Pancre... Stage IV Prosta... Stage IV Uterin... Thyroid Gland C...	Questionnaire A... Biospecimen Col...	40 Years - 75 Years	Alliance for Clinical Trials in Oncology
Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer	NCT01463072	Locally Advance... Metastatic Brea... Recurrent Breas... Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast...	Laboratory Biom... Nab-paclitaxel Questionnaire A...	65 Years -	City of Hope Medical Center

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: